Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Disease × Temozolomide × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 373 Brain Neoplasms 148 Glioma 143 Gliosarcoma 120 Astrocytoma 107 Central Nervous System Neoplasms 101 Oligodendroglioma 68 Neuroblastoma 39 Medulloblastoma 30 Ependymoma 26 Recurrence 22 Neoplasms 18 Diffuse Intrinsic Pontine Glioma 15 Neoplasm Metastasis 14 Choroid Plexus Neoplasms 11 Melanoma 10 Optic Nerve Glioma 9 Spinal Cord Neoplasms 8 Rhabdomyosarcoma 8 Osteosarcoma 8 Breast Neoplasms 8 Neuroectodermal Tumors, Primitive 7 Lymphoma 7 Familial ependymoma 7 Sarcoma, Ewing 6 Sarcoma 6 Rhabdoid Tumor 6 Neuroectodermal Tumors, Primitive, Peripheral 6 Glioma, Subependymal 6 Wilms Tumor 5

Interventions

pembrolizumab 2 fluciclovine F-18 2 neratinib 1 alovudine 1 Temozolomide 1 Oncolytic Virotherapy 1 Magnetic Resonance Spectroscopy 1 Interleukin-15 1 Cyclophosphamide 1 Antibodies, Monoclonal 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00660283 2010-01-20

KARE003

Kentuckiana Cancer Institute

Phase 2 Unknown

Disease, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡